PMID- 33377312
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1610-0387 (Electronic)
IS  - 1610-0379 (Linking)
VI  - 19
IP  - 1
DP  - 2021 Jan
TI  - Comparative efficacy and safety of biologics in moderate to severe plaque 
      psoriasis: a multiple-treatments meta-analysis.
PG  - 47-56
LID - 10.1111/ddg.14308 [doi]
AB  - OBJECTIVE: To compare the efficacy and safety of biologics for patients with 
      moderate to severe plaque psoriasis. METHODS: We systematically reviewed 60 
      randomized controlled trials (34,020 participants), which compared 14 biological 
      drugs for treatment of moderate to severe plaque psoriasis. The main assessment 
      criteria were >/= 90 % reductions in Psoriasis Area and Severity Index (PASI 90) 
      and the number of patients who reported treatment-emergent adverse events (AEs). 
      Secondary criteria were >/= 75 % reductions in Psoriasis Area and Severity Index 
      (PASI 75), Physician's Global Assessment 0/1 (PGA 0/1) and infections. RESULTS: 
      This network meta-analysis showed that biologics were significantly more 
      effective than placebo. Ixekizumab, risankizumab, and bimekizumab were among the 
      most effective treatments, and tildrakizumab, guselkumab and risankizumab were 
      better than the other drugs with respect to safety. Risankizumab and guselkumab 
      performed relatively stable with respect to both efficacy and safety. At the 
      class level, blockers of interleukin (IL)-17A showed favorable efficacy while 
      inhibitors of the p19 subunit of IL-23 were best tolerated of all efficient 
      biologics. CONCLUSIONS: Ixekizumab was the most effective biologic in PASI 90, 
      while IL-23p19 inhibitors, risankizumab and guselkumab performed relatively 
      stable with respect to efficacy and safety.
CI  - (c) 2020 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & 
      Sons Ltd.
FAU - Xu, Shanshan
AU  - Xu S
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Anhui 
      Medical University, Hefei, Anhui, China.
AD  - The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, Hefei, 
      Anhui, China.
FAU - Gao, Xing
AU  - Gao X
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Anhui 
      Medical University, Hefei, Anhui, China.
AD  - The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, Hefei, 
      Anhui, China.
FAU - Deng, Jixiang
AU  - Deng J
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Anhui 
      Medical University, Hefei, Anhui, China.
AD  - The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, Hefei, 
      Anhui, China.
FAU - Yang, Jiajia
AU  - Yang J
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Anhui 
      Medical University, Hefei, Anhui, China.
AD  - The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, Hefei, 
      Anhui, China.
FAU - Pan, Faming
AU  - Pan F
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Anhui 
      Medical University, Hefei, Anhui, China.
AD  - The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, Hefei, 
      Anhui, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201230
PL  - Germany
TA  - J Dtsch Dermatol Ges
JT  - Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German 
      Society of Dermatology : JDDG
JID - 101164708
RN  - 0 (Biological Products)
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - *Biological Products
MH  - Humans
MH  - Immunosuppressive Agents
MH  - *Psoriasis
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2020/12/31 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/12/30 05:26
PHST- 2019/12/07 00:00 [received]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
PHST- 2020/12/30 05:26 [entrez]
AID - 10.1111/ddg.14308 [doi]
PST - ppublish
SO  - J Dtsch Dermatol Ges. 2021 Jan;19(1):47-56. doi: 10.1111/ddg.14308. Epub 2020 Dec 
      30.